There are no available data on gadopiclenol use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. GBCAs cross the human placenta and result in fetal exposure and gadolinium retention. The available human data on GBCA exposure during pregnancy and adverse fetal outcomes are limited and inconclusive.L49866
In animal reproduction studies, there were no adverse developmental effects observed in rats or rabbits with intravenous administration of gadopiclenol during organogenesis. Because of the potential risks of gadolinium to the fetus, use gadopiclenol only if imaging is essential during pregnancy and cannot be delayed.L49866
In subjects that received a single intravenous dose of gadopiclenol (0.3 mmol/kg) that corresponded to 6 times the recommended dose, headache and nausea were the most frequently reported adverse reactions. Gadopiclenol can be removed from the body by hemodialysis.L43817 Carcinogenicity studies of gadopiclenol have not been performed. Gadopiclenol showed no evidence of mutagenicity in in vitro and in vivo assays. An in vivo study performed in rats showed that up to 10 mmol/kg (62 times the recommended human dose), gadopiclenol did not affect fertility and general reproductive performance.L43817
Gadopiclenol is a gadolinium-based contrast agent (GBCA) based on a pyclen macrocyclic structure. It is indicated for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system and the body.L43817 In 2006, the use of GBCAs was associated with the development of nephrogenic systemic fibrosis (NSF), a rare disorder characterized by the thickening and hardening of skin and subcutaneous tissues. However, studies revealed that NSF was associated with linear GBCAs, not macrocyclic GBCAs, such as gadopiclenol.A254002 Gadopiclenol has high kinetic stability and a high r1 relaxivity, allowing it to be used at lower doses than classic extracellular GBCAs.A254002,A254017
In September 2022, the use of gadopiclenol was approved by the FDA. The product label includes a black box warning regarding the increased risk for NSF among patients with impaired elimination of the drugs.L43817
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.